Spruce Biosciences, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Spruce Biosciences, Inc. (SPRB) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $47.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-12
- Spruce Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $5.17M.
- Spruce Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$13.14M.
- Spruce Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$15.19M, a 130.85% decline year-over-year.
- Spruce Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $49.22M.
- Spruce Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $10.15M.
- Spruce Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$57.59M, a 180.38% decline from fiscal 2023.
- Spruce Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $71.64M.
- Spruce Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$18.23M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $47.39M 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $5.17M 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $10.15M 10-K · filed 2026-03-09 | |||
| 2025-09-30 | -$28.08M 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | -$22.37M 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | -$13.14M 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | -$57.59M 10-K · filed 2026-03-09 | |||
| 2024-09-30 | -$36.28M 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | -$26.66M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$15.19M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $71.64M 10-K · filed 2025-04-15 | |||
| 2023-09-30 | $74.10M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $72.78M 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | $49.22M 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | -$18.23M 10-K · filed 2024-03-18 | |||
| 2022-09-30 | -$21.10M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $4.46M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$19.41M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | -$114.40M 10-K · filed 2023-03-16 | |||
| 2021-09-30 | -$98.79M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | -$78.87M 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | -$8.52M 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | $153.44M 10-K · filed 2022-03-14 | |||
| 2020-09-30 | $68.45M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $32.89M 10-Q · filed 2021-08-10 | |||
| 2020-03-31 | $37.70M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | -$188.00K 10-K · filed 2021-03-22 | |||
| 2019-09-30 | $720.00K 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |